Effectiveness and Limitations of Spiramycin for Toxoplasmosis During Pregnancy: A Systematic Review

https://doi.org/10.22146/jmpf.100761

Noor Laila Harkaningdyah(1*), Salma Auliya Fatimah(2), Ayu Anggresti(3), Lavia Dinta Nur Pratiwi(4), Nabila Risti Rachmadi(5), Andi Desiah Pranada(6)

(1) Master in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(2) Master in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(3) Master in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(4) Master in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(5) Master in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(6) Master in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract


Background: Toxoplasmosis is brought on by the protozoan parasite Toxoplasma gondii. Toxoplasmosis can be transferred from a mother to her fetus during pregnancy, resulting in congenital illness. Spiramycin is administered in the early stages as a kind of prophylaxis for the fetus and can be continued until delivery. If the fetus becomes infected, therapy is altered to a triple mixture of sulfadiazine, folinic acid, and pyrimethamine.

Objectives: This article aims to comprehensively review spiramycin as a prophylactic measure for preventing vertical transmission of infection to fetuses and its limitations, including adverse effects.

Methods: This study used a systematic review approach of publications indexed in Scopus, PubMed, ScienceDirect, and Web of Science databases from 2014 to 2024. It utilized the PRISMA flow diagram to guide the article selection process until a conclusion was reached.

Results: Based on the predetermined inclusion and exclusion criteria and in accordance with the topic of this research objective, six research articles were suitable for review. Among the six reviewed articles, spiramycin is the first-line therapy for preventing vertical transmission of Toxoplasma gondii to the fetus. The most common side effect of using spiramycin in pregnant women is paresthesia.

Conclusion: Spiramycin has an important role in preventing congenital toxoplasmosis, but it is not recommended for infected fetuses. Instead, combination therapy is superior for treating infections that have occurred in the fetus.


Keywords


Gestational; Pregnancy; Spiramycin; Toxoplasmosis

Full Text:

PDF


References

  1. Hatam-Nahavandi K, Calero-Bernal R, Rahimi MT, et al. Toxoplasma gondii infection in domestic and wild felids as public health concerns: a systematic review and meta-analysis. Sci Rep. 2021;11(1):9509. doi:10.1038/s41598-021-89031-8
  2. Alday H, Doggett J. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther. 2017;Volume11:273-293. doi:10.2147/DDDT.S60973
  3. Ahmed M, Sood A, Gupta J. Toxoplasmosis in Pregnancy. EJOG. 2020;255:44-50. Accessed October 15, 2024. https://www.ejog.org/article/S0301-2115(20)30632-1/abstract
  4. Manuel L, Santos-Gomes G, Noormahomed E V. Human toxoplasmosis in Mozambique: gaps in knowledge and research opportunities. Parasit Vectors. 2020;13(1):571. doi:10.1186/s13071-020-04441-3
  5. Prasil P, Sleha R, Kacerovsky M, Bostik P. Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus? Journal of Maternal-Fetal and Neonatal Medicine. 2023;36(1). doi:10.1080/14767058.2023.2215377
  6. Chaudhry S, Gad N, Koren G. Toxoplasmosis and Pregnancy. Can Fam Physician. 2014;60(4):334-336. Accessed October 15, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046541/
  7. Abdel-Wahab AA, Shafey DA, Selim SM, et al. Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model. Parasitol Res. 2024;123(7):286. doi:10.1007/s00436-024-08280-4
  8. Damar Çakırca T, Can İN, Deniz M, Torun A, Akçabay Ç, Güzelçiçek A. Toxoplasmosis: A Timeless Challenge for Pregnancy. Trop Med Infect Dis. 2023;8(1). doi:10.3390/tropicalmed8010063
  9. Çakır A, Memiş H, Gün ZÜ, Bıçakcıoğlu M. Evaluation of Drug-Related Problems of Intensive Care Unit Patients by Clinical Pharmacists: A Retrospective Study. Turk J Pharm Sci. 2024;21(4):274-283. doi:10.4274/tjps.galenos.2023.44459
  10. Yulianty MD, Cahaya N, Srikartika VM. Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. JSFK : Jurnal Sains Farmasi dan Klinis. 2017;3(2):153-164.
  11. Diesel AA, Zachia SDA, Müller ALL, Perez AV, Uberti FADF, Magalhães JADA. Follow-up of Toxoplasmosis during Pregnancy: Ten-Year Experience in a University Hospital in Southern Brazil. Revista Brasileira de Ginecologia e Obstetricia. 2019;41(9):539-547. doi:10.1055/s-0039-1697034
  12. Losa A, Carvalho I, Sousa B, et al. Congenital Toxoplasmosis Diagnosis: Challenges and Management Outcomes. Cureus. Published online January 26, 2024. doi:10.7759/cureus.52971
  13. Avelino MM, Amaral WN, Rodrigues IM. Congenital Toxoplasmosis and Prenatal Care State Programs. Published online 2014. Accessed January 8, 2026. http://www.biomedcentral.com/1471-2334/14/33
  14. Valentini P, Buonsenso D, Barone G, et al. Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy. Journal of Perinatology. 2015;35(2):90-94. doi:10.1038/jp.2014.161
  15. Paquet C, Yudin MH, Yudin MH, et al. Toxoplasmosis in Pregnancy: Prevention, Screening, and Treatment. Journal of Obstetrics and Gynaecology Canada. 2013;35(1):78-79. doi:10.1016/S1701-2163(15)31053-7
  16. Department of Health G of SA. South Australian Perinatal Practice Guideline Toxoplasmosis in Pregnancy. 2018. Accessed October 15, 2024. https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/resources/policies/toxoplasmosis+in+pregnancy+-+sa+perinatal+practice+guidelines
  17. Contact. Australian Pregnancy Care Guidelines. https://livingevidence.org.au/living-guidelines/leapp/
  18. BNF for Children. BNF for Children September 2022-2023. BMJGroup; 2023.
  19. Maldonado YA, Read JS. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics. 2017;139(2). doi:10.1542/peds.2016-3860
  20. Brook I. Pharmacodynamics and Pharmacokinetics of Spiramycin and Their Clinical Significance. Clin Pharmacokinet. 2012;34(4):303-310. doi:10.2165/00003088-199834040-00003
  21. Mandelbrot L, Kieffer F, Sitta R, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(4):386.e1-386.e9. doi:10.1016/j.ajog.2018.05.031
  22. De Santis M, Tartaglia S, Apicella M, et al. The prevention of congenital toxoplasmosis using a combination of Spiramycin and Cotrimoxazole: The long‐time experience of a tertiary referral centre. Tropical Medicine & International Health. 2024;29(8):697-705. doi:10.1111/tmi.14021
  23. Buonsenso D, Pata D, Turriziani Colonna A, et al. Spyramicine and Trimethoprim-Sulfamethoxazole Combination to Prevent Mother-To-Fetus Transmission of Toxoplasma gondii Infection in Pregnant Women: A 28-Years Single-center Experience. Pediatric Infectious Disease Journal. 2022;41(5):e223-e227. doi:10.1097/INF.0000000000003469
  24. Valentini P, Annunziata ML, Angelone DF, et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. European Journal of Clinical Microbiology & Infectious Diseases. 2009;28(3):297-300. doi:10.1007/s10096-008-0612-5
  25. Sadeghi M, Hosseini SA, Sarvi S, et al. Enhanced clindamycin delivery using chitosan-coated niosomes to prevent Toxoplasma gondii strain VEG in pregnant mice: an experimental study. Trop Med Health. 2024;52(1):64. doi:10.1186/s41182-024-00636-x
  26. Hotop A, Hlobil H, Gross U. Efficacy of Rapid Treatment Initiation Following Primary Toxoplasma gondii Infection During Pregnancy. Clinical Infectious Diseases. 2012;54(11):1545-1552. doi:10.1093/cid/cis234
  27. Buonsenso D, Pata D, Turriziani Colonna A, et al. Spyramicine and Trimethoprim-Sulfamethoxazole Combination to Prevent Mother-To-Fetus Transmission of Toxoplasma gondii Infection in Pregnant Women: A 28-Years Single-center Experience. Pediatric Infectious Disease Journal. 2022;41(5):e223-e227. doi:10.1097/INF.0000000000003469
  28. Shibuya et al. An open-label study of the tolerability and pharmacokinetics of a single oral dose of spiramycin in healthy Japanese and caucasian women (TDU14412). Therapeutic Research. 2017;38(3):301-310.
  29. Yakovlev S V., Suvorova МР. The Renaissance of Spiramycin in Clinical Practice. Antibiot Chemother (1971). 2023;68(7-8):83-89. doi:10.37489/0235-2990-2023-68-7-8-83-89
  30. Apolikhina AIA, Suleimanova SZhZh, Teterina TTA. The potential of spiramycin in modern gynecological practice. Akush Ginekol (Mosk). 2025;10_2025:173-179. doi:10.18565/aig.2025.259
  31. Mandelbrot L, Kieffer F, Sitta R, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(4):386.e1-386.e9. doi:10.1016/j.ajog.2018.05.031
  32. Telaku S, Islamaj E, Veliu A, et al. The Efficacy of Spiramycin-based Triple Therapy for First-Line Helicobacter Pylori Eradication. Pharmakeftiki. 2023;34(4).
  33. Sinta Maharani, Ika Restu Kaeksi, Nisa Wahyuningsih, Mega Kurnia Mutiara, Liss Dyah Dewi Arini. Toksoplasmosis Kehamilan. NAJ : Nursing Applied Journal. 2025;3(1):36-45. doi:10.57213/naj.v3i1.517
  34. CASP. CASP Checklist: For Cohort Studies. CASP. 2024. Accessed February 18, 2026. https://casp-uk.net/casp-checklists/CASP-checklist-cohort-study-2024.pdf
  35. CASP. CASP Checklist: For Descriptive/Cross-Sectional Studies. CASP. 2024. Accessed February 18, 2026. https://casp-uk.net/casp-checklists/CASP-checklist-cross-sectional-study-2024.pdf



DOI: https://doi.org/10.22146/jmpf.100761

Article Metrics

Abstract views : 2 | views : 8

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats